摘要
目的:探讨腹腔热灌注化疗(HIPEC)治疗进展期胃癌的疗效及安全性。方法:选取接受手术治疗的进展期胃癌患者79例为研究对象,均已经病理检查确诊,随机分为观察组(36例)和对照组(43例)。观察组接受手术联合HIPEC治疗,对照组仅进行手术及术后辅助治疗。比较两组围手术期指标、肿瘤标志物指标、术后胃癌复发转移及患者生存情况。结果:观察组腹痛、骨髓抑制、消化道症状占比高于对照组(均P<0.05)。术前两组癌胚抗原(CEA)和糖类抗原199(CA199)水平比较差异无统计学意义(均P>0.05),化疗6周期后观察组CEA水平低于对照组(P<0.05),CA199水平与对照组比较差异无统计学意义(P>0.05)。术后1年内,观察组患者吻合口、原发灶、腹腔内复发占比低于对照组(P<0.05),肝、肺等远处转移以及病死率与对照组比较差异无统计学意义(均P>0.05)。结论:HIPEC可协同术后辅助化疗,安全、有效地改善进展期胃癌患者的术后生存状态,降低血清CEA水平,减少术区局部复发率。
Objective:To investigate the efficacy and safety of hyperthermic intraperitoneal chemotherapy(HIPEC)foRadvanced gastric cancer.Methods:Seventynine patients with advanced gastric canceRwho underwent surgery were included in the study,all of whom had a pathological diagnosis,and were randomly divided into observation group(36 cases)and control group(43 cases).The observation group received surgery in combination with HIPEC,and the control group underwent surgery and postoperative adjuvant therapy.Perioperative parameters,tumoRmarkers,recurrence and metastasis of gastric cancer,and patient survival were compared between the two groups.Results:The proportions of abdominal pain,bone marrow depression,and gastrointestinal symptoms were higheRin the observation group than those in the control group(all P<0.05).Before operation,there was no significant difference in the levels of CEA and CA199 between two groups(all P>0.05);afteR6 cycles of chemotherapy,the CEA level in the observation group was loweRthan that in the control group(P<0.05),but there was no significant difference in CA199 level between two groups(P>0.05).Conclusion:HIPEC can cooperate with adjuvant chemotherapy,safely and effectively improve postoperative survival in patients with advanced gastric cancer,reduce serum CEA level,and reduce local recurrence rate in the surgical field.
作者
王浩南
曹军
WANG Haonan;CAO Jun(Department of Surgical Oncology,the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)
出处
《陕西医学杂志》
CAS
2022年第12期1560-1563,共4页
Shaanxi Medical Journal
基金
陕西省自然科学基础研究计划项目(2021JM-263)。
关键词
进展期胃癌
腹腔热灌注化疗
围手术期
肿瘤标志物
安全性
Advanced gastric cancer
Hyperthermic intraperitoneal chemotherapy
Peroperative period
TurmoRmarker
Safety
